Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=18 Medtronic CoreValve REDO Study
Aortic Valve Stenosis
Primary: Percentage of MAE Free Subjects — 10 Participants
N/A N=733 Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
Cardiovascular Disease · Coronary Artery Disease
Primary: To Compare 1-year Angiographic Patency of Radial Artery Grafts Versus Saphenous Vein Grafts in Patients Undergoing Elective Coronary Artery Bypass Graft (CABG) Surgery…
Phase 4 N=500 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass · Antiplatelet Agents
Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts
Phase 3 N=2,136 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
Phase 4 N=411 On Versus Off Pump Myocardial Revascularization Study
Coronary Artery Disease
Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants
N/A N=1,500 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Coronary Disease · Coronary Stenosis
Primary: MACCE — 80; 51 Participants — p=0.35
Phase 2 N=11 AZD8601 Study in CABG Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 7; 4 Participants
Phase 2 N=56 Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
Coronary Artery Bypass Grafting · Cardiopulmonary Bypass · Reperfusion Injury
Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 4 N=250 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion — 17.4; 13.2 percentage of veins occluded
N/A N=2,203 ROOBY Trial Follow-up Extension
All Cause Mortality · MACE
Primary: Long-term All Cause Mortality Between On-pump and Off-pump Patients. — 131; 168; 298; 342 Participants
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=224 A Prospective Randomized Study for Comparison of Y-Composite Grafts
Coronary Artery Disease
Primary: 1 Year Graft Patency Rates — 97.1; 97.1 percentage of distal anastomoses
Phase 2 N=100 Quercetin in Coronary Artery By-pass Surgery
Coronary Artery Disease
Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L
Phase 4 N=84 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
Surgery · Coronary Artery Disease
Primary: Time to Extubation — 10.4; 6 Minutes
Phase 2 N=113 Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
Atherosclerosis
Primary: Vein Graft Intimal Area — 4.1; 4.5 mm
Phase 3 N=173 Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year — 14; 16 Vein grafts
N/A N=200 Hybrid Coronary Revascularization Trial
Coronary Artery Disease
Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year
N/A N=453 Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery
Cardiovascular Diseases · Coronary Disease · Heart Diseases
Primary: Generic Mental Health-Related Quality of Life — 50.0; 46.2; 57.2 units on a scale
N/A N=116 Comparison of Bidirectional Palpation Test and Transit Time Flow Measurement for LIMA-LAD Graft Patency
Coronary Arterial Disease (CAD) · Coronary Artery Bypass · LIMA
Primary: Reliability of Bidirectional Palpation Test (BPT) in Evaluating LIMA-LAD Graft Patency — 2; 2; 2; 2 Participants — p=<0.001
Phase 2 N=448 Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia
Coronary Artery Bypass Surgery
Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
Phase 2 N=33 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass Graft · Cardiopulmonary Bypass
Primary: Incidence of Adverse Events — 3; 3; 5; 4 participants
Phase 4 N=20 Reversing Ticagrelor's Effects With Fresh Platelets
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18